ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

VRP Verona Pharma Plc

55.00
0.00 (0.00%)
26 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Verona Pharma Plc LSE:VRP London Ordinary Share GB00BYW2KH80 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 55.00 45.00 65.00 - 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Verona Pharma Share Discussion Threads

Showing 13201 to 13224 of 13325 messages
Chat Pages: 533  532  531  530  529  528  527  526  525  524  523  522  Older
DateSubjectAuthorDiscuss
15/4/2022
10:58
...busy drifting down..... nothing new here.....
haff1
24/2/2022
13:20
....busy going no where......
haff1
22/2/2022
11:15
...didn't need one for Covid!
haff1
04/2/2022
09:26
Hard to speed up a pivotal phase 3 clinical trial!
tradertrev
04/2/2022
09:21
...the usual slow drawn out dissappointment we are use to here, I note!
haff1
29/12/2021
14:26
I've also held a few of these since the days of reasonable hope (c.8 years I think???) I'd more or less given up on them having managed to lose close to 60% on the effers, and was just looking. With a mkt cap of now $422m, surely it's all over as regards any potential excitement? I'd be very glad to hear that I'm wrong though; any thoughts from anyone who half knows what they're talking about :-) ??
boystown
28/12/2021
09:57
I have also been in since 2009 and suffered the massive dilution. However, The recent cardiac results were good and no doubt required by the FDA. I also remember there were cases in an earlier trial, with an
Increase in heart rate, so it’s good that is not deemed to be problem. I am also very happy that the P3 end point targets are based on FEV and general improvement in well being. FEV has always been good in every previous trial, so I personally believe that the prospects for success are good, and on that basis, I look forward to 2022.

digger18
24/12/2021
11:38
...Back to where they nearly were before! But lets hope the surge continues....
haff1
24/12/2021
09:39
Blimey, these have actually gone up! Hearing the shares have attracted some broker support Stateside, but not seen the articles myself.
tradertrev
01/12/2021
11:00
I probably started my holding 6-7 years ago, so I share a fair bit of your pain!
tradertrev
01/12/2021
09:55
I've been in VRP for over 10 years and it's yet to stand up to its original potential. It's been increditably slow and has seen constant devaluation of the share price from the start....
haff1
30/11/2021
12:08
what is it that you expected to have happened by now that hasn't?
They've set out a clear timetable by which things should happen and are broadly sticking to it.
I'd agree the waiting seems endless, but in reality it isn't.

tradertrev
30/11/2021
10:45
...the dissappointment here seems endless......
haff1
29/9/2021
11:42
....beginning to think there isn't even jam tomorrow..........
haff1
05/8/2021
22:21
While the Q2 report suggests the possibility of some slippage in the Phase 3 timelines due to study recruitment challenges amid the continuing pandemic (not really a surprise) there does however appear to be some improvement in the liquidity runway:

Q2 comment - The Company believes our cash and cash equivalents at June 30, 2021, together with the recently received $25.0 million Nuance payment, the recent and anticipated future receipts from the U.K. tax credit program and funding expected to become available under the $30.0 million debt financing facility secured in November 2020 will enable us to fund our planned operating expenses and capital expenditure requirements THROUGH AT LEAST 2023. (my capitals)

Q1 comment - We believe that our cash and cash equivalents as of March 31, 2021, and together with funding expected to become available under both the Term Loan and from cash receipts from U.K. tax credits will enable us to fund our planned operating expenses and capital expenditure requirements INTO 2023. (my capitals)

During Q2 the company issued and sold the equivalent of 54,338 ADSs at average price of $7.23 raising c.$0.4m under their ($100m) At The Market issuance/sale facility. This is effectively a tap facility and explains why any share price surges are always short-lived. Management seem determined to keep a lid on the share price!!

tradertrev
03/8/2021
12:44
...will this ever fly?
haff1
07/7/2021
10:34
Bid offer spread a meagre 51% on last night's close!!!
tradertrev
02/7/2021
10:13
...but investers see it as too far off to be interested as yet......
haff1
10/6/2021
14:35
now this is what we've been waiting for for years.....this is very good news for VRP..
haff1
10/6/2021
12:00
Vote of confidence in the product
haroldthegreat
10/6/2021
11:58
from a friend...

Nuance founder Mark Lotter built AstraZeneca's business in China, which has been highly successful in the respiratory market.
Nuance has a nebuliser platform of its own.
Nuance owns the rights in China to Parexel's Exparel, a significant product already in the US. Parexel would not have licensed this product to any old outfit.

Could be better news than it first appeared. Last trade in pre-market at $7.70 according to Seeking Alpha

tradertrev
10/6/2021
08:14
A bit of good news released this morning (for a change).....
timbo003
20/5/2021
08:51
Almost 700k ADRs traded over the past two days. Hopefully we are clearing an overhang, although perhaps not fully done yet.
tradertrev
19/5/2021
09:40
Need the share price to follow......
haff1
Chat Pages: 533  532  531  530  529  528  527  526  525  524  523  522  Older

Your Recent History

Delayed Upgrade Clock